Patrick Forde, Professor of Thoracic Oncology at Johns Hopkins University, shared a post on X:
“Looking forward to Joshua Reuss presenting the first results of neoadjuvant/perioperative combined nivo +/- ipi in mesothelioma. How will the standard of care for unresectable meso perform as neoadj therapy? Trial includes cutting edge liquid biopsy data.”
More from Patrick Forde on OncoDaily.